Eve Health Group
- Short interest
- <0.01%
- 0.00 pp 30d
- as of 18 Aug 2020
- Reported shorts
- 19.3K
- Shares on issue
- 3.726B
Eve Health Group (EVE) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $1.2Mvs $1.7M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- −$1.9Mvs −$1.6M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.006T (source: Derived: trailing 12 months at year end)vs −$0.011 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −33.5%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Summary of Annual Report to shareholders, 31 Aug 2026
EVE Health Group reported a year of commercial execution with early revenue from Libbo® and Dyspro® launches, though specific revenue and net profit figures were not disclosed in the provided excerpt. No dividend was declared. The company expanded its reformulation pipeline and advanced Libbo® toward a pivotal bioequivalence study, with plans to pursue licensing partnerships for international markets.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 27 Oct 2026
- Gross margin
- 45.7%
- Operating margin
- −164.8%
- Net margin
- −164.0%
- FCF margin
- −151.2%
- ROE
- −50.4%
- ROA
- −45.0%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 4.3×
- Interest cover
- −605.8×
- Cash dividends paid / net profit
- n/a
- Market cap
- $4.6M
- P/E
- n/a
- P/B
- 1.2×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $1.2M | $1.7M | $2.1M | $2.3M |
| Gross profit | $527.5K | $824.0K | $877.0K | $827.8K |
| Operating income | −$1.9M | −$1.4M | −$1.5M | −$2.4M |
| EBITDA | −$1.8M | −$1.4M | −$1.5M | −$2.2M |
| EBIT | −$1.9M | −$1.4M | −$1.5M | −$2.4M |
| Interest expense | $3.1K | $27.1K | $34.9K | n/a |
| Pretax income | −$1.9M | −$1.5M | −$1.5M | −$2.3M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$1.9M | −$1.6M | −$1.9M | −$3.1M |
| Net interest income | −$3.1K | −$27.1K | −$34.9K | $118 |
| EPS basic | −$0.006T (source: Derived: trailing 12 months at year end) | −$0.011 | −$0.016 | −$0.024 |
| EPS diluted | −$0.006T (source: Derived: trailing 12 months at year end) | −$0.011 | −$0.016 | −$0.024 |
| Shares | 352.3M | 137.5M | 131.9M | 131.9M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Annual Report to shareholdersAnnual Report31 Aug 2026via asx_announcements
- Appendix 4EAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report - AmendedQuarterly Report7 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4EAnnual Results29 Aug 2025via asx_announcements
- Annual Report to shareholdersAnnual Report29 Aug 2025via asx_announcements
Showing 10 of 20 reports